Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Coronavirus COVID-19 General Research

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

Two vials of Covid-19 vaccines, one marked first dose and other marked second dose
  • Com-COV 3 to test multiple options for second dose COVID-19 vaccines in young people aged 12 to 16 years
  • Participants immunised with first dose of Pfizer-BioNtech to receive either second full dose Pfizer-BioNtech, half dose Pfizer-BioNtech, half dose Moderna or full dose Novavax – eight-week interval
  • Researchers to assess reactogenicity and immunogenicity of vaccine schedules

Backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR) and run across four NIHR-supported sites by the National Immunisation Schedule Evaluation Consortium, the Com-COV 3 trial will seek to recruit 360 volunteers.

Read the full story on the University of Oxford website

Similar stories